Insider Trading March 24, 2026

AE Red Holdings Trims Stake in Redwire as Company Advances Commercial and NASA Work

Minor sale by a 10% holder coincides with new contracts, board additions and an analyst upgrade for Redwire

By Sofia Navarro RDW
AE Red Holdings Trims Stake in Redwire as Company Advances Commercial and NASA Work
RDW

AE Red Holdings, a roughly 10% owner and director in Redwire Corp (NASDAQ: RDW), sold 27,190 shares on March 20, 2026, for $273,531. The sale took place at a weighted average price of $10.06 with executed prices reported between $10.00 and $10.04. Redwire has since moved to $9.06 per share but remains up 23% year-to-date. The company has secured a $12.8 million commercial contract for its ELSA solar array wings, received a $4 million NASA award for space-based drug development, added Frank Calvelli to its board, and was upgraded to buy by Truist Securities, which raised its price target to $15.

Key Points

  • AE Red Holdings sold 27,190 Redwire shares on March 20, 2026, at a weighted average price of $10.06, totaling $273,531; sale prices ranged from $10.00 to $10.04.
  • After the sale AE Red Holdings retains 43,635,217 shares of Redwire; the stock has since fallen to $9.06 but is up 23% year-to-date amid high volatility.
  • Redwire secured a $12.8 million commercial contract for ELSA solar array wings, received a $4 million NASA award for drug development on the ISS, added Frank Calvelli to its board, and was upgraded to buy by Truist, which set a $15 price target.

AE Red Holdings, which holds a roughly ten percent stake and a director position at Redwire Corp (NASDAQ:RDW), executed a sale of 27,190 common shares on March 20, 2026. The transaction generated total proceeds of $273,531 and was completed at a reported weighted average price of $10.06. The individual sale prices recorded for the transaction ranged from $10.00 to $10.04.

Following the disposition, AE Red Holdings remains a significant shareholder with 43,635,217 shares of Redwire outstanding under its ownership. Market movement after the trade saw Redwire shares decline to $9.06, though the stock is still higher by 23% year-to-date amid notable volatility.

Independent equity analysis referenced by InvestingPro indicates that Redwire appears undervalued relative to Fair Value estimates. The InvestingPro briefing also notes that additional proprietary tips and financial metrics are available to subscribers for deeper scrutiny.


Operationally, Redwire has been advancing both commercial and government work. The company announced a $12.8 million contract to supply Extensible Low-Profile Solar Array wings to Moog Inc., described as the first commercial sale of the ELSA product. Separately, Redwire received a $4 million award from NASA to support drug development investigations aboard the International Space Station, an effort that builds on the company’s prior work under NASA’s In Space Production Applications program.

In governance developments, Redwire added Frank Calvelli, a former Air Force space acquisition chief, to its board of directors. The company also disclosed progress in its manufacturing and production programs. Truist Securities upgraded Redwire’s rating to buy, citing improvements in product mix and production programs and reporting that 33% of Redwire’s programs are now in full rate production. Alongside the upgrade, Truist increased its price target for the company to $15 per share.

Redwire has been promoting its new ELSA solar array product aimed at mass-produced satellites. The company states that ELSA provides up to 50% more power by volume compared with traditional solar arrays, positioning the product as a standardized power solution for satellite platforms.


This report leaves the core facts of the insider sale and company developments intact. The scope of the information here is limited to the transaction details, the firm’s disclosed contracts, board appointment, analyst action, and InvestingPro observations as reported.

Risks

  • Share-price volatility: Redwire’s stock moved from the sale price down to $9.06, reflecting short-term volatility that may affect investor returns and market perception - impacts equity investors and market participants.
  • Valuation ambiguity: While InvestingPro indicates the stock appears undervalued based on Fair Value estimates, such assessments carry uncertainty and may not reflect near-term market pricing - impacts valuation-focused investors and analysts.
  • Execution and production risk: Truist’s commentary notes that 33% of programs are in full rate production, implying that the majority of programs remain in earlier stages of ramping, presenting execution risk for manufacturing and program delivery - impacts aerospace and space-systems suppliers.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026